Cytokine and human leukocyte antigen (HLA) profile for graft-versus-host disease (GVHD) after organ transplantation
- Xinhua Chen†1, 2,
- Xueqin Meng†1, 2,
- Yuning Xu1, 2,
- Haiyang Xie1, 2,
- Shengyong Yin1, 2,
- Hongchun Li3,
- Liming Wu1, 2Email author and
- Shusen Zheng1, 2Email author
© The Author(s) 2016
Received: 1 March 2016
Accepted: 30 September 2016
Published: 12 October 2016
Graft-versus-host disease (GVHD) after liver and kidney transplantation has high mortality and causes diagnostic challenges. This study aims to describe the cytokine and human leukocyte antigen (HLA) profile in the GVHD after liver and kidney transplantation.
A high-throughput detection kit was applied and altogether 18 different cytokines were tested simultaneously. GVHD patients included 23 post-liver transplantation patients; 22 post-renal transplantation patients; The control patients include 22 hepatocellular carcinoma (HCC) patients without transplantation and 20 healthy controls. Their HLA characters were compared.
The full spectrum of cytokines was present. The inflammatory markers were activated significantly in liver transplantation. The level of inflammatory markers in liver transplantation was higher than that in renal transplantation, HCC or healthy controls. GVHD was associated with the HLA characters; HLA characters are involved in liver GVHD occurrence and act as risk factors.
Our findings confirmed that the inflammatory cytokines play a pathogenic role in GVHD and can be used as early diagnostic markers. The HLA mismatch acts as a risk factor in liver transplantation to predict GVHD occurrence.
KeywordsCytokine Human leukocyte antigen (HLA) Graft-versus-host disease (GVHD) Transplantation Multiplex immunoassay High-throughput
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death in the world [1, 2] and China accounts for almost half of HCC cases . The liver transplantation is the curative treatment for HCC but post-transplantation graft-versus-host disease (GVHD) has caused mortality [3, 4]. The cytokine and HLA profile of GVHD can help understand the inflammatory background and the risk factors [5, 6]. The full profile of cytokine in the cytokine storms post GVHD is still lacking. In this study, we present a high-throughput cytokine exam for GVHD after liver and kidney transplantation. The association with HLA was also analyzed.
Altogether, 87 patients were included: 23 HCC patients with liver transplantation (LT); 22 renal transplantation (RT); 22 HCC without transplantation (HCC); and 20 healthy controls (control). Patients underwent organ transplant between January 2004 and December 2014.
Measurement of cytokines by multiplex immunoassay
The multiple cytokines were measured by Multiplex Immunoassay Kit (Affymetrix, CA, USA). Briefly, 25 μL serum and standards were incubated with pre-mixed beads coated with antibodies. After washing, plates were incubated with the detection antibody and the reaction revealed with streptavidin–phycoerythrin. The beads were analyzed on a Luminex system (Bio-Rad, USA) for the concentration of the following 18 cytokines: IL-10, IL-17A, IL-21, IL-22, IL-23, IL-27, IL-9, GM-CSF, IFN-γ, IL-1b, IL-12, P70, IL-13, IL-18, IL-2, IL-4, IL-5, IL-6, TNF-α.
Pathological confirmation of the skin biopsy
The pathological slides of the biopsy were reviewed and the pathological figures to support the diagnosis of GVHD was present. The skin sample was stained and read by two independent pathologists. The hematoxylin–eosin (H&E) was stained for the confirmation of GVHD.
The anti-HLA antibody measurement
The HLA antibodies were measured by Luminex technology (One Lambda, Inc. Canoga Park, CA, USA). According to the manufacturer’s manual book, HLA-specific antibodies were identified using immune beads coated with purified HLA antigens. HLA antibodies in patient’s serum were bound to the antigens coated on the beads. The complex was then stained with R-phycoerythrin-conjugated goat anti-human IgG. The fluorescent emission of R-phycoerythrin was measured and then analyzed by HLA analysis software (Canoga Park, CA, USA.). All adjusted and normalized reactions that were above 500 were considered positive.
The present data are expressed as mean ± SD. For statistical comparison of values, Student’s t test was used. P values less than 0.05 were deemed to indicate statistical significance. The SPSS one-way analysis of variance (ANOVA) was used to determine whether there were any statistically significant differences.
The clinical presentation
The clinical characteristics of patients
Number of patients
Recipient age (years)
54 ± 19
49 ± 12
58 ± 9
51 ± 21
Time to onset (days)
253 ± 39
192 ± 51
22 ± 2.1
19 ± 3.4
20 ± 2.8
23 ± 3.2
56 ± 4
61 ± 2
45 ± 4
52 ± 3
35 ± 2
28 ± 1
31 ± 3
31 ± 2
Total bilirubin (mg/dL)
0.95 ± 0.11
0.95 ± 0.16
0.95 ± 0.23
0.95 ± 0.37
Direct bilirubin (mg/dL)
0.45 ± 0.09
0.35 ± 0.14
0.47 ± 0.15
0.30 ± 0.17
9.6 ± 2.1
4.8 ± 1.7
3.6 ± 0.4
4.5 ± 1.1
12 ± 2
11 ± 3
10 ± 2
14 ± 2
Screening of cytokines
The pathology of skin lesion biopsy
Different from kidney transplantation, which requires a strict donor–recipient HLA matching to improve long-term prognosis, liver transplantation can tolerate the HLA-mismatching to some degree. The incompatibility between donor and recipient might inhibit the host immune function. Whether HLA-B matching and the other HLA loci may impact long-term survival in liver transplantation is still debating [12, 13]. We use it as a risk factor rather than an absolute evaluation biomarker.
There are three basic requirements formulated by Billingham in 1966 for the development of GVHD: the graft must contain immunologically competent cells; the recipient must express tissue antigens that are not present in the transplant donor; and the recipient must be incapable of mounting an effective response to eliminate the transplanted cells [7–9]. Our results proved that GVHD post liver transplantation involved HLA mismatch and inflammatory cytokine release.
Examining the levels and interplay of cytokines can help to identify GVHD biomarkers and medical intervention targets . However, the complicated interactions of cytokine network in GVHD can only be understood when the full cytokine profile is present . Multiplex immune-assays can detect multiple cytokines with a small amount of patient’s serum (only 25 μL) with good parallel among different cytokines. The multiplex luminescence immunoassay can simultaneously detect antibody activity to 18 antigens in a single 96-well plate. The exam can be performed automatically in a centralized laboratory. The results indicate that after GVHD onset, an exaggerated response of cytokines IL2, IL18, IFN-γ may predispose to GVHD. They can be used to predict the occurrence of GVHD in transplant recipients. High levels of the three cytokines above correlated with the development of GVHD. The results suggest that measurement of IL2, IL18 and IFN-γ is of predictive value. Beside IL2, IL18 and IFN-r, the baseline of other 15 cytokines were also present (IL-10, IL-17A, IL-21, IL-22, IL-23, IL-27, IL-9, GM-CSF, IL-1b, IL-12P70, IL-13, IL-4, IL-5, IL-6, TNF-α). These results together provide a full cytokine profile and further substantiate the complex cytokine cascade that is initiated by GVHD.
Another notable finding in our study is the cytokine difference between GVHD post liver transplantation and renal transplantation. The GVHD and cytokine situation in liver transplantation and renal transplantation is quite different. IL2, IL18 and IFN were all lower in RT group than other groups. To address this difference, we have to add an additional HLA-typing experiment to explain the reason. The renal transplantation requires a very strict HLA matching. So, all renal transplantation cases were HLA-matched. The GVHD in renal transportation and inflammation response were not as high as that in liver transplantation. The strict HLA match in renal transplantation might be the possible reason. We added a typical case of LT to show its HLA-typing. HLA-mismatching allows patient to survive in liver transplantation without acute rejection. But it did increase the risk of GVHD in long term.
The immune mechanism on GVHD involves T cells and B cells. However, it is becoming increasingly focused on host-derived molecules that result from tissue incompatibility, e.g., HLA-mismatching . Our result showed that HLA contribute to the occurrence of GVHD and then the rejection reaction was so wide that it caused skin damage. An improved understanding of these pathways may reveal novel therapeutic targets to decrease GVHD and increase long-term survival.
One major risk factor for the development of GVHD after LT was determined: human leukocyte antigen (HLA) matching between the donor and the recipient; Donor–recipient compatibility for HLA-B was identified as a significant risk factor for the development of GVHD. An accurate diagnosis of GVHD depends on histological and immuno-histochemical proof . In our study, the pathological in skin include lymphocyte infiltration, basal cell vacuolization and the keratinocyte resembling. The differential diagnosis excluded the bacterial, viral and fungal causes of gastrointestinal symptoms. Then, the patients were given standard treatment of increased immune suppression and antibody preparations. Immune suppressants are a necessary right after transplant surgeries, preventing the rejection-caused new organ function failure. But the long term use of immune suppressants can cause many side effects such as infection, cancer, diabetes, GVHD compared to the general population. The proper withdrawal or minimize the use of immune suppression can help the immune system reconstitute itself.
Our study provides a comprehensive platform for GVHD diagnosis. The HLA-mismatching works as a risk factor for the physician to suspect the high possibility of occurrence. Cytokine profile can be used for early diagnosis. Skin biopsy can be used as confirmation.
Our findings confirmed that the inflammatory cytokines play a pathogenic role in GVHD and can be used as early diagnostic markers and future therapeutic targets. The HLA mismatch acts as risk factor in liver transplantation to predict GVHD occurrence.
cytokine and human leukocyte antigen
XC designed the experiment and drafted the manuscript. XM carried out the HLA studies and collected the data, YX carried out the immunoassays. HX, SY, HL participated in the design of the study and performed the statistical analysis. LW and SZ conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
Authors thank Miss Lin Zhang for collecting clinical information and Dr. Ke Sun for providing pathology slides.
The authors declare that they have no competing interests.
Availability of data and material
Please contact author for data requests.
Ethics approval and consent to participate
This comparative study of a retrospective cohort was approved by the Ethical Committee of the First Affiliated Hospital of Zhejiang University.
Natural Science Foundation of China (81372425, 81572954, 81401319, 81421062, 91542205), Zhejiang Science Project (2013T301-15, LY13H180003, 2013C37002, 2016C33145), SanMing Project of Shenzhen City.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L, Yan S, Wu L, Geng L, Ke Q, Gao F, Tu Z, Wang W, Zhang M, Shen Y, Xie H, Jiang W, Wang H, Zheng S. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut. 2016;65(6):1035–41.View ArticlePubMedGoogle Scholar
- Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011;21(6):401–16.View ArticlePubMedPubMed CentralGoogle Scholar
- Chaib E, Silva FD, Figueira ER, Lima FR, Andraus W, D’Albuquerque LA. Graft-versus-host disease after liver transplantation. Clinics. 2011;66(6):1115–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Green T, Hind J. Graft-versus-host disease in paediatric solid organ transplantation: a review of the literature. Pediatr Transplant. 2016;20(5):607–18.View ArticlePubMedGoogle Scholar
- Mihăilă RG. Liver graft versus host disease after allogeneic peripheral stem cell transplantation: update on etiopathogenesis and diagnosis. Rom J Intern Med. 2016;54(2):83–92.PubMedGoogle Scholar
- Magenau J, Runaas L, Reddy P. Advances in understanding the pathogenesis of graft-versus-host disease. Br J Haematol. 2016;173(2):190–205.View ArticlePubMedGoogle Scholar
- Leveque-El Mouttie L, Koyama M, Le Texier L, Markey KA, Cheong M, Kuns RD, Lineburg KE, Teal BE, Alexander KA, Clouston AD, Blazar BR, Hill GR, MacDonald KP. Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. Blood. 2016;128(6):794–804.View ArticlePubMedGoogle Scholar
- Elfeki MA, Pungpapong S, Genco PV, Nakhleh RE, Nguyen JH, Harnois DM. Graft-versus-host disease after orthotopic liver transplantation: multivariate analysis of risk factors. Clin Transplant. 2015;29(12):1063–6.View ArticlePubMedGoogle Scholar
- Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E, Kreft A, Longerich T, Morton T, Myerson D, Prieto VG, Rosenberg A, Treister N, Washington K, Ziemer M, Pavletic SZ, Lee SJ, Flowers ME, Schultz KR, Jagasia M, Martin PJ, Vogelsang GB, Kleiner DE. NIH, consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 pathology working group report. Biol Blood Marrow Transplant. 2015;21(4):589–603.View ArticlePubMedPubMed CentralGoogle Scholar
- Hellwig Y, Yoo YE, Reß ML, Andres O, Braun M, Schlegel PG, Wölfl M. Fulminant skin GvHD with a cytokine pattern resemblant of cytokine release syndrome successfully treated with multimodal immunosuppression including tocilizumab. Pediatr Blood Cancer. 2015;62(11):2033–5.View ArticlePubMedGoogle Scholar
- Thiant S, Moutuou MM, Leboeuf D, Guimond M. Homeostatic cytokines in immune reconstitution and graft-versus-host disease. Cytokine. 2016;82:24–32.View ArticlePubMedGoogle Scholar
- Uchiyama H, Kayashima H, Matono R, Shirabe K, Yoshizumi T, Ikegami T, Soejima Y, Matsuura T, Taguchi T, Maehara Y. Relevance of HLA compatibility in living donor liver transplantation: the double-edged sword associated with the patient outcome. Clin Transplant. 2012;26(5):E522–9.View ArticlePubMedGoogle Scholar
- Murali AR, Chandra S, Stewart Z, Blazar BR, Farooq U, Ince MN, Dunkelberg J. Graft versus host disease after liver transplantation in adults: a case series, review of literature, and an approach to management. Transplantation. 2016. PMID: 27495762 (Epub ahead of print).